Literature DB >> 29610193

FDA Approves Lutathera for GEP NET Therapy.

.   

Abstract

Entities:  

Year:  2018        PMID： 29610193

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  4 in total

1.  Targeted Radionuclide Therapy in Patient-Derived Xenografts Using 177Lu-EB-RGD.

Authors:  Liang Zhao; Haojun Chen; Zhide Guo; Kaili Fu; Lanling Yao; Li Fu; Weixi Guo; Xuejun Wen; Orit Jacobson; Xianzhong Zhang; Long Sun; Hua Wu; Qin Lin; Xiaoyuan Chen
Journal:  Mol Cancer Ther       Date:  2020-08-26       Impact factor: 6.261

2.  Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute.

Authors:  Cristina Müller; Maria De Prado Leal; Marco D Dominietto; Christoph A Umbricht; Sairos Safai; Rosalind L Perrin; Martina Egloff; Peter Bernhardt; Nicholas P van der Meulen; Damien C Weber; Roger Schibli; Antony J Lomax
Journal:  Pharmaceutics       Date:  2019-09-02       Impact factor: 6.321

3.  Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy.

Authors:  Haojun Chen; Liang Zhao; Kaili Fu; Qiuming Lin; Xuejun Wen; Orit Jacobson; Long Sun; Hua Wu; Xianzhong Zhang; Zhide Guo; Qin Lin; Xiaoyuan Chen
Journal:  Theranostics       Date:  2019-10-16       Impact factor: 11.556

Review 4.  Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications.

Authors:  Riccardo Laudicella; Domenico Albano; Salvatore Annunziata; Diletta Calabrò; Giovanni Argiroffi; Elisabetta Abenavoli; Flavia Linguanti; Domenico Albano; Antonio Vento; Antonio Bruno; Pierpaolo Alongi; Matteo Bauckneht
Journal:  Cancers (Basel)       Date:  2019-09-22       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.